KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Amortization - Intangibles (2022 - 2025)

Halozyme Therapeutics (HALO) has disclosed Amortization - Intangibles for 4 consecutive years, with $23.4 million as the latest value for Q4 2025.

  • Quarterly Amortization - Intangibles rose 31.61% to $23.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $76.7 million through Dec 2025, up 7.9% year-over-year, with the annual reading at $76.7 million for FY2025, 7.9% up from the prior year.
  • Amortization - Intangibles for Q4 2025 was $23.4 million at Halozyme Therapeutics, up from $17.8 million in the prior quarter.
  • The five-year high for Amortization - Intangibles was $27.2 million in Q3 2022, with the low at $4.6 million in Q4 2022.
  • Average Amortization - Intangibles over 4 years is $17.6 million, with a median of $17.8 million recorded in 2023.
  • Peak annual rise in Amortization - Intangibles hit 290.2% in 2023, while the deepest fall reached 25.2% in 2023.
  • Over 4 years, Amortization - Intangibles stood at $4.6 million in 2022, then skyrocketed by 290.2% to $17.8 million in 2023, then changed by 0.0% to $17.8 million in 2024, then surged by 31.61% to $23.4 million in 2025.
  • According to Business Quant data, Amortization - Intangibles over the past three periods came in at $23.4 million, $17.8 million, and $17.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.